Comparing two methods of nerve blocks for lung surgery
The Impact of Ultrasound-Guided Superficial and Deep Paravertebral Nerve Blocks at the Superior Costotransverse Ligament on Hemodynamics During the Induction Phase of Thoracoscopic Lung Lobectomy: A Multicenter, Double-Blind, Randomized Controlled Trial
This study is testing which of two nerve block techniques helps people having lung surgery feel better and recover more comfortably.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 168 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06841822 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of two different ultrasound-guided paravertebral nerve block techniques during the induction phase of thoracoscopic lung lobectomy. Participants will be randomly assigned to receive either a superficial or deep paravertebral block to assess which method better maintains hemodynamic stability. The study aims to enroll 168 patients across five hospitals, focusing on optimizing pain management and recovery outcomes. By comparing these techniques, the trial seeks to enhance postoperative comfort and reduce the need for general anesthesia.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older scheduled for elective two-port video-assisted thoracoscopic lobectomy with an ASA classification of I-III.
Not a fit: Patients with severe hypertension, significant cardiovascular disease, or other serious health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved hemodynamic stability and postoperative recovery for patients undergoing lung surgery.
How similar studies have performed: Previous studies have shown promise in using ultrasound-guided nerve blocks for similar surgical procedures, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients scheduled for elective two-port video-assisted thoracoscopic lobectomy * Age: ≥18 years * ASA classification: I-III * BMI: 18-30 kg/m² Exclusion Criteria: * Severe hypertension (SBP ≥180 mmHg or DBP ≥110 mmHg) * MAP \<70 mmHg before anesthesia induction * Emergency surgery * Severe cardiovascular disease, including history of cerebral or thoracic/abdominal aortic aneurysm * Congestive heart failure (New York Heart Association class III or IV) * Untreated or unstable ischemic heart disease * Severe aortic or mitral valve disease * Pregnancy or lactation * Coagulation disorders * Bacteremia, sepsis, or infection at the puncture site * Allergy to study-related drugs * Severe liver and kidney dysfunction * Neurological disorders, spinal disease (deformity or trauma), history of spinal surgery, or abnormal skin sensation in the thoracic or back region * Existing or anticipated difficult airway management * Other conditions deemed unsuitable for inclusion by the investigators Forty patients who required CT (3D) imaging technology to observe drug diffusion after the implementation of the two methods were included as follows: patients who were scheduled to undergo double-hole thoracoscopic lobectomy, aged ≥18 years, ASA grade I to III, BMI 18 to 30kg/m2, and required preoperative CT localization. Exclusion criteria In addition to the above conditions, patients with a history of anaphylaxis induced by contrast agents should be excluded.
Where this trial is running
Nanjing, Jiangsu
- Nanjing First Hospital — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Yajie Xu
- Email: xuyajiechina@163.com
- Phone: 86 18651815258
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.